Evidence map›Paper›PMID 40801326›Full record

ArticleCancer research communications2025

Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population.

Brendan M Giles, Rachel Culp-Hill, Robert A Law, Charles M Nichols, Mattie Goldberg, Enkhtuya Radnaa, Maria Wong, Connor Hansen, Moises Zapata, Collin Hill and 11 more

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Brendan M GilesAOA Dx, Denver, Colorado.ORCID 0009-0002-2867-0201
Rachel Culp-HillAOA Dx, Denver, Colorado.ORCID 0000-0003-3000-083X
Robert A LawAOA Dx, Denver, Colorado.ORCID 0009-0009-5371-4350
Charles M NicholsAOA Dx, Denver, Colorado.ORCID 0000-0001-9398-3410
Mattie GoldbergAOA Dx, Denver, Colorado.ORCID 0009-0005-9570-9307
Enkhtuya RadnaaAOA Dx, Denver, Colorado.ORCID 0000-0001-8142-8137
Maria WongAOA Dx, Denver, Colorado.ORCID 0009-0000-2337-6244
Connor HansenAOA Dx, Denver, Colorado.ORCID 0009-0008-8609-4031
Moises ZapataAOA Dx, Denver, Colorado.ORCID 0009-0008-4727-5833
Collin HillAOA Dx, Denver, Colorado.ORCID 0009-0001-7906-0481
Kian BehbakhtUniversity of Colorado Anschutz Medical Campus, Denver, Colorado.ORCID 0000-0003-4793-9958
Benjamin G BitlerUniversity of Colorado Anschutz Medical Campus, Denver, Colorado.ORCID 0000-0002-5809-5271
Emma J CrosbieDivision of Cancer Sciences, University of Manchester, Manchester, United Kingdom.ORCID 0000-0003-0284-8630
Chloe E BarrDivision of Cancer Sciences, University of Manchester, Manchester, United Kingdom.ORCID 0000-0002-4013-5001
Anna JeterAOA Dx, Denver, Colorado.ORCID 0009-0002-9757-3536
Vuna S FaAOA Dx, Denver, Colorado.ORCID 0009-0009-7864-8572
Violeta Beleva GuthrieAOA Dx, Denver, Colorado.ORCID 0000-0002-5526-4957
Leonardo N HagmannAOA Dx, Denver, Colorado.ORCID 0000-0002-2723-3547
Emily C KubotaAOA Dx, Denver, Colorado.ORCID 0000-0002-6387-1239
James Robert WhiteResphera Biosciences, Baltimore, Maryland.ORCID 0000-0002-7535-9179
Abigail McElhinnyAOA Dx, Denver, Colorado.ORCID 0009-0007-5656-0321

Funding

National Institute for Health and Care Research (NIHR) NIHR203308National Institute for Health and Care Research (NIHR) NIHR300650
6 · The paper itself

Abstract

Ovarian cancer is the fifth leading cause of cancer-related deaths among women. Most patients are diagnosed at late stage (III/IV), resulting in a 5-year survival rate below 30%. This is driven by the presentation of vague abdominal symptoms that confound diagnosis at early stages (I/II) and a shortage of robust biomarkers. We are taking a novel approach for earlier ovarian cancer detection, leveraging lipids as biomarkers. We utilized untargeted ultrahigh pressure liquid chromatography-mass spectrometry to analyze sera from two large, independent cohorts (N = 433 and N = 399) designed to reflect the symptomatic population, including individuals with benign adnexal masses, early- and late-stage ovarian cancer, gastrointestinal disorders, and otherwise healthy women seeking care for symptoms. We identified a significantly altered lipid profile in ovarian cancer and early-stage ovarian cancer specifically across both cohorts compared with controls. We also profiled select protein biomarkers (cancer antigen 125, human epididymis protein 4, β-2 folate receptor α, and mucin 1) and, utilizing machine learning-based modeling, identified a proof-of-concept multiomic model consisting of less than 20 top-performing lipid and protein features. This model was trained on cohort 1 and tested on cohort 2, achieving AUCs of 92% (95% confidence interval, 87%-95%) for distinguishing ovarian cancer from controls and 88% (95% confidence interval, 83%-93%) for distinguishing early-stage ovarian cancer from controls. These findings demonstrate the clinical utility and robustness of lipids as proof-of-concept diagnostic biomarkers for early ovarian cancer within the clinically complex symptomatic population, particularly when applied in a multiomic approach. SIGNIFICANCE: Patients with ovarian cancer endure delayed diagnosis and poor outcomes. We profiled lipids in two cohorts and integrated them with proteins in machine learning. This enabled early-stage detection in a complex range of controls.

Indexed as

Biomarkers, TumorEarly Detection of CancerLipidomicsLipidsMachine LearningOvarian NeoplasmsAdultAgedCase-Control StudiesFemaleHumansMiddle AgedBiomarkers, TumorLipids

Identifiers

PMID40801326
PMCPMC12409608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.